Increase CRC screening rates

One test, one goal, improved CRC screening

We appreciate opportunities to collaborate with you on scaling colorectal cancer (CRC) solutions, patient support in informed decision-making, and the Cologuard® test.
Physician reviewing CRC screening rates on a large lightboard with six monitors.
Scalable CRC screening solutions
See how the Cologuard test can help close the CRC screening gap.
Physician introducing informed decision making and discussing colorectal cancer screening options with a patient who is sitting on an exam table.
Advocating for patient choice in CRC screening
Informed decision-making with CRC screening can enhance patient experiences and improve adherence.1
A healthcare provider reviewing a document with 4 health system leaders around a table.
Strategies to boost CRC screening rates and adherence
See the support for how the Cologuard test can boost CRC screening rates and adherence.4,5
Four healthcare providers having a discussion in a healthcare setting.
Best-in-class, noninvasive detection
Learn how the Cologuard test delivers best-in-class, noninvasive CRC screening for average risk patients 45+.2,3

References

  1. Laiyemo AO, Adebogun AO, Doubeni CA, et al. Influence of provider discussion and specific recommendation on colorectal cancer screening uptake among U.S. adults. Prev Med. 2014;67:1-5. 
  2. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
  3. Cologuard® Clinician Brochure. Madison, WI: Exact Sciences Corporation. 
  4. Prince M, Lester L, Chiniwala R, Berger B. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients. World J Gastroenterol. 2017;23(3):464-471. 
  5. Data on file. Exact Sciences Corporation. Madison, WI.

Indications and Important Risk Information

The Cologuard® test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by colonoscopy. The Cologuard test is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC. The Cologuard test is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

The Cologuard test is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months; have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease; or have a family history of colorectal cancer, or certain hereditary syndromes.

Positive Cologuard results should be referred to colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.

False positives and false negatives do occur. In a clinical study, 13% of patients without colorectal cancer or advanced adenomas received a positive result (false positive) and 8% of patients with cancer received a negative result (false negative). The clinical validation study was conducted in patients 50 years of age and older. Cologuard test performance in patients ages 45 to 49 years was estimated by sub-group analysis of near-age groups.

Cologuard test performance when used for repeat testing has not been evaluated or established. Rx only